



Atty. Docket No. A34690 070050.1714
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
MAY 28 2003
TECH CENTER 1600/2900

Applicant : Fisher *et al.*
Serial No. : 09/621,781 Examiner : Loeb, Bronwen
Filed : July 21, 2000 Group Art Unit : 1636
For : NUCLEIC ACIDS COMPRISING REGIONS OF THE RAT PEG-3
PROMOTER THAT DISPLAY ELEVATED EXPRESSION IN HUMAN
CANCER CELLS AND USES THEREOF

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT


I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231

May 22, 2003

Date of Deposit

Lisa B. Kole

Attorney Name


Signature

35,225

PTO Registration No.

May 22, 2003

Date of Signature

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 C.F.R. §1.56 and §1.97(c)(2), Applicants respectfully request that the references relating to the above-identified application listed herein in reverse chronological alphabetical order be considered and made of record in the U.S. Patent and Trademark Office.

05/27/2003 HBLANCO 00000012 09621781

01 FC:1806

180.00 DP

NY02:409727.1

1. International Patent Application No. PCT/US01/23099, filed July 20, 2001, entitled "NUCLEIC ACIDS COMPRISING REGIONS OF THE RAT PEG-3 PROMOTER AND USES THEREOF", published as WO 02/08242 on January 31, 2002, by the Trustees of Columbia University in the City of New York;
2. Hacein-Bey-Abina S *et al.*, 2002, "Sustained Correction of X-Linked Severe Combined Immunodeficiency by ex Vivo Gene Therapy" *N Engl J Med.* 346(16):1185-1193;
3. Liu Y *et al.*, 2002, "In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma" *Cancer Gene Ther.* 9(1):9-15;
4. Losordo D W *et al.*, 2002, "Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia" *Circulation* 105(17):2012-2018;
5. Rosen F S, 2002, "Successful Gene Therapy for Severe Combined Immunodeficiency" (Editorial) *N Engl J Med.* 346(16):1241-1243;
6. Stolberg S G, October 4, 2002, "Trials are halted on gene therapy", *New York Times*, page A1, column 3;
7. Wang H Y *et al.*, 2002, "Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells" *J Clin Invest.* 109(11):1463-1470;
8. International Patent Application No. PCT/US00/34564, filed December 20, 2000, entitled "PROGRESSIVE ELEVATED GENE-3 (PEG-3) INDUCES AGGRESSIVE CANCER PHENOTYPE AND REGULATES ANGIOGENESIS", published as WO 01/46386 on June 28, 2001, by the Trustees of Columbia University in the City of New York;
9. Melero I *et al.*, 2001, "IL-12 gene therapy for cancer: in synergy with other immunotherapies" *Trends Immunol.* 22(3):113-115;
10. Sarkar N *et al.*, 2001, "Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease--12-month follow-up: angiogenic gene therapy" *J Intern Med.* 250(5):373-381;
11. Schenk G *et al.*, 2001, "Gene therapy: future therapy for erectile dysfunction" *Curr Urol Rep.* 2(6):480-487;
12. DOE Joint Genome Institute, June 29, 2000, Genbank Accession No. AC073828;
13. Anderson W F, 2000, "Gene therapy: the best of times, the worst of times" *Science* 288:627-629;
14. Cavazzana-Calvo *et al.*, 2000, "Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease" *Science* 288:669-672;

15. De Giovanni C *et al.*, 2000, "The prospects for cancer gene therapy" *Int J Immunopharmacol.* 22(12):1025-1032;
16. Kay M A *et al.*, 2000, "Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector" *Nat Genet.* 24(3):257-261;
17. Park F *et al.*, 2000, "Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver" *Blood* 96(3):1173-1176;
18. Soares C R *et al.*, 2000, "High-level synthesis of human prolactin in Chinese-Hamster ovary cells" *Biotechnol Appl Biochem.* 32(Pt 2):127-135;
19. Somia and Verma, 2000, "Gene therapy: trials and tribulations" *Nat Rev Genet.* 1(2):91-99;
20. Stiens L R *et al.*, 2000, "Development of serum-free bioreactor production of recombinant human thyroid stimulating hormone receptor" *Biotechnol Prog.* 16(5):703-709;
21. Su *et al.*, July 13 2000, "Cooperation between AP1 and PEA3 sites within the progression elevated gene-3 (PEG-3) promoter regulate basal and differential expression of PEG-3 during progression of the oncogenic phenotype in transformed rat embryo cells" *Oncogene* 19(30):3411-3421.
22. Su *et al.*, "Defining the regions within the promoter of progression elevated gene-3 responsible for differential expression during transformation progression", abstract submitted to be presented at the 91st Annual Meeting of the American Association for Cancer Research" in April 2000 but, according to e-mail correspondence from inventor Paul Fisher, never published.
23. Symes J F, 2000, "Focal angiogenic therapy for myocardial ischemia" *J Card Surg.* 15(4):283-290;
24. International Patent Application No. PCT/US99/07199, filed March 31, 1999, entitled "PROGRESSION ELEVATED-3 GENE AND USES THEREOF", published as WO 99/49898 on October 9, 1999, by the Trustees of Columbia University in the City of New York;
25. Kumar A *et al.*, 1999, "Large-scale propagation of recombinant adherent cells that secrete a stable form of human glandular kallikrein, hK2" *Protein Expr Purif.* 15(1):62-68;
26. Lode H N *et al.*, 1999, "Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12" *Proc Natl Acad Sci USA* 96(15):8591-8596;

27. Su ZZ et al., 1999, "PEG-3, a nontransforming cancer progression gene, is a positive regulator of cancer aggressiveness and angiogenesis" *Proc. Natl. Acad. Sci.* 96(26):15115-15120;
28. Toda M et al., 1999, "Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity" *Hum Gene Ther.* 10(3):385-393;
29. United States Patent No. 6,472,520 by Fisher, for "RAT PEG-3 PROMOTER", filed March 31, 1998 and issued October 29, 2002;
30. United States Patent No. 6,146,877 by Fisher, for "IDENTIFICATION OF THE PROGRESSIVE-ELEVATED GENE-3 AND USES THEREOF", filed March 31, 1997 and issued November 14, 2000;
31. Karin M et al., 1997, "Current Opinion in Cell Biology" *AP-1 function and regulation* 9:240-246;
32. Olive M et al., 1997, "A Dominant Negative to Activation Protein-1 (AP1) That Abolishes DNA Binding and Inhibits Oncogenesis" *The Journal of Biological Chemistry*, 272(30):18586-18594;
33. D'Orazio D et al., 1997, "Cooperation of two PEA3/AP1 sites in uPA gene induction by TPA and FGF-2¹" *Gene*, 201:179-187;
34. De Cesare D et al., 1996, "Functional characterization of COM, a DNA region required for cooperation between AP-1 sites in urokinase gene transcription" *Oncogene* 13:2551-2562;
35. Schweighoffer T et al., 1996, "Adenovirus-enhanced receptor-mediated transferrin infection for the generation of tumor vaccines" *Cytokines Mol Ther.* 2(3):185-191;
36. Kohn E et al., 1995, "Molecular Insights into Cancer Invasion: Strategies for Prevention and Intervention" *Cancer Research* 55:1856-1862;
37. Higashino F et al., 1995, "Ets-related protein E1A-F can activate three different matrix metalloproteinase gene promoters" *Oncogene* 10:1461-1463;
38. Stacey K et al., 1995, "Regulation of Urokinase-Type Plasminogen Activator Gene Transcription by Macrophage Colony-Stimulating Factor" *Molecular And Cellular Biology* 15(6):3430-3441;
39. Hartwell L et al., 1994, "Cell Cycle Control and Cancer" *Science* 266(16):1821-1828;
40. Matrisian L M et al., 1994, "Matrix Metalloproteinase Gene Expression" *Annals New York Academy of Sciences* 732:42-50;
41. Vogelstein B et al., 1993, "The multistep nature of cancer" *TIG* 9(4):138-141;

42. Knudson A *et al.*, 1993, "Antioncogenes and human cancer" *Proc. Natl. Acad. Sci. USA* 90:10914-10921;
43. Levine A *et al.*, 1993, "The Tumor Suppressor Genes" *Annu. Rev. Biochem.* 62:623-51;
44. Reddy P *et al.*, 1993, "Identification and Cloning of Genes Involved in Progression of Transformed Phenotype" *Methods in Molecular Genetics* 1:68-102;
45. Wasylyk B *et al.*, 1993, "The Ets family of transcription factors" *Eur. J. Biochem.* 211:7-18;
46. Edwards D *et al.*, 1992, "Involvement of AP1 and PEA3 binding sites in the regulation of murine tissue inhibitor of metalloproteinases-1 (TIMP-1) transcription" *Biochimica et Biophysica Acta.* 1171:41-55;
47. Brown T *et al.*, 1992, "Specificities of protein-protein and protein-DNA interaction of GABP α and two newly defined ets-related proteins" *Genes & Development* 6:2502-2512;
48. Macleod K *et al.*, 1992, "The ets gene family" *TIBS* 17(7):251-256;
49. Nerlov C *et al.*, 1992, "A regulatory element that mediates co-operation between a PEA3-AP-1 element and an AP-1 site is required for phorbol ester induction of urokinase enhancer activity in HepG2 hepatoma cells" *The EMBO Journal* 11(12):4573-4582;
50. Angel P *et al.*, 1991, "The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation" *Biochimica et Biophysica Acta* 1072:129-157;
51. Bishop M J *et al.*, 1991, "Molecular Themes In Oncogenesis" *Cell* 64:235-248;
52. Sirum-Connolly K *et al.*, 1991, "Interleukin-1 or phorbol induction of the stromelysin promoter requires an element that cooperates with AP-1" *Nucleic Acids Research* 19(2):335-341;
53. Duigou G J *et al.*, 1991, "Analysis of viral and cellular gene expression during progression and suppression of the transformed phenotype in type 5 adenovirus-transformed rat embryo cells" *Oncogene* 6:1813-1824;
54. Liotta L A *et al.*, 1991, "Cancer Metastasis and Angiogenesis: An Imbalance of Positive and Negative Regulation" *Cell* 64:327-336;
55. Duigou G J *et al.*, 1990, "Suppression of the Progression Phenotype in Somatic Cell Hybrids Occurs in the Absence of Altered Adenovirus Type 5 Gene Expression" *Molecular And Cellular Biology* 10(5):2027-2034;
56. Gutman A *et al.*, 1990, "The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites" *The EMBO Journal* 9(7):2241-2246;

57. Matrisian L M *et al.*, 1990, "Stromelysin/transin and tumor progression" *Seminars in Cancer Biology* 1:107-115;
58. Duigou G J *et al.*, 1989, "Suppression of the Progression Phenotype by 5-Azacytidine in Rat Embryo Cells Doubly Transformed by Type 5 Adenovirus and the Ha-ras Oncogene" *Annals New York Academy of Science* 567:302-306;
59. Wasylyk C *et al.*, 1989, "PEA3 is a nuclear target for transcription activation by non-nuclear oncogenes" *The EMBO Journal* 8(11):3371-3378;
60. Babiss L E *et al.*, 1985, "Reversibility of Progression of the Transformed Phenotype in Ad5-Transformed Rat Embryo Cells" *Science* 228:1099-1101;
61. Fisher P B *et al.*, 1984, "Mechanisms of Tumor Promotion" *Slaga T.J. (ed) CRC Press, Inc., Boca Raton, FL*, 3:57-123;
62. Dignam J D *et al.*, 1983, "Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei" *Nucleic Acids Research* 11(5):1475-1489;
63. Fisher P B *et al.*, 1982, "Analysis of type 5 adenovirus transformation with a cloned rat embryo cell line (CREF)" *Proc. Natl. Acad. Sci. USA* 79:3527-3531;
64. Fisher P B *et al.*, 1979, "Tumor Promoters and Epidermal Growth Factor Stimulate Anchorage-Independent Growth of Adenovirus-Transformed Rat Embryo Cells" *Cell* 18:695-705;
65. Fisher P B *et al.*, 1979, "Tumor Promoters Enhance Anchorage-Dependent Growth of Adenovirus-Transformed Cells without Altering the Integration Pattern of Viral Sequences" *Nature* 281:591-594;
66. Fisher P B *et al.*, 1979, "Phenotypic Properties and Tumor Promoter-induced Alterations in Rat Embryo Cells Transformed by Adenovirus" *Cancer Research* 39:3051-3057; and
67. Fisher P B *et al.*, 1978, "Interactions between adenovirus, a tumor promoter, and chemical carcinogens in transformation of rat embryo cell cultures" *Proc. Natl. Acad. Sci. USA* 75(5):2311-2314.

The Examiner's attention is particularly invited to references 21 and 22, which are in bold-face text. The referenced citations are listed in the accompanying PTO Form 1449. Copies of the references are submitted herewith in two bound volumes. A copy of the Search

Report received by Applicants in connection with International Application No.


PCT/US01/23099 is also enclosed herewith.

Identification of the references listed in the attached PTO Form 1449 is not to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the above-identified application.

Applicants enclose herewith the fee required under 37 C.F.R. §1.17(p). Any required fees not otherwise enclosed herewith may be charged to Deposit Account No. 02-4377.

Two copies of this page are enclosed.

Respectfully submitted,



Henry Tang
PTO Reg. No. 29,705

Lisa B. Kole
PTO Reg. No. 35,225

Attorney for Applicants
BAKER BOTTS, L.L.P.
30 Rockefeller Plaza
New York, NY 10112
(212) 408-2628

May 22, 2003

Enclosures
Form PTO-1449
Copies of cited documents

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A34690 (070050.1714)		Serial No. 09/621,781
	Applicant Fisher, <i>et al.</i>		
	Filing Date July 21, 2000	Group 1636	
	(Empty space for additional information)		

U.S. PATENT DOCUMENTS

*Exam. Init.	Document No.	Date	Name	Class	Subclass	Filing Date if Appro.
	29 6 4 7 2 5 2 0	10/29/2002	Fisher			3/31/1998
	30 6 1 4 6 8 7 7	11/14/2000	Fisher			3/31/1997

FOREIGN PATENT DOCUMENTS

Document No.	Date	Country	Class	Subclass	Translation Yes No
1 WO 02/08242	1/31/2002	WIPO			
8 WO 01/46386	6/28/2001	WIPO			
24 WO 99/49898	10/9/1999	WIPO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

2	Hacein-Bey-Albina S <i>et al.</i> , 2002, "Sustained Correction of X-Linked Severe Combined Immunodeficiency by ex Vivo Gene Therapy" <i>N Engl J Med.</i> <u>346</u> (16): 1185-1193.
3	Liu Y <i>et al.</i> , 2002, "In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma" <i>Cancer Gene Ther.</i> <u>9</u> (1):9-15.
4	Losordo D W <i>et al.</i> , 2002, "Phase ½ placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia" <i>Circulation</i> <u>105</u> (17):2012-2018.
5	Rosen F S, 2002, "Successful Gene Therapy for Severe Combined Immunodeficiency" (Editorial) <i>N Engl J Med.</i> <u>346</u> (16):1241-1243.

NY02:415587.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34690 (070050.1714)	Serial No. 09/621,781
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher, <i>et al.</i>	
	Filing Date July 21, 2000	Group 1636

RECEIVED
MAY 28 2003
TECH CENTER 1600/26000

6	Stolberg S G, 2002, "Trials are halted on gene therapy" <i>New York Times</i> , page A1, column 3.
7	Wang H Y <i>et al.</i> , 2002, "Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells" <i>J Clin Invest.</i> <u>109</u> (11):1463-1470.
9	Melero I <i>et al.</i> , 2001, "IL-12 gene therapy for cancer: in synergy with other immunotherapies" <i>Trends Immunol.</i> <u>22</u> (3):113-115.
10	Sarkar N <i>et al.</i> , 2001, "Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease—12-month follow-up: angiogenic gene therapy" <i>J Intern Med.</i> <u>250</u> (5):373-381.
11	Schenk G <i>et al.</i> , 2001, "Gene therapy: future therapy for erectile dysfunction" <i>Curr Urol Rep.</i> <u>2</u> (6):480-487;
12	DOE Joint Genome Institute, June 29, 2000, Genbank Accession No. AC073828;
13	Anderson W F, 2000, "Gene therapy: the best of times, the worst of times" <i>Science</i> <u>288</u> :627-629.
14	Cavazzana-Calvo <i>et al.</i> , 2000, "Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease" <i>Science</i> <u>288</u> :669-672.
15	De Giovanni C <i>et al.</i> , 2000, "The prospects for cancer gene therapy" <i>Int J Immunopharmacol.</i> <u>22</u> (12):1025-1032.
16	Kay M A <i>et al.</i> , 2000, "Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector" <i>Nat Genet.</i> <u>24</u> (3):257-261.
17	Park F <i>et al.</i> , 2000, "Therapeutic levels of human factor VIII and IX using HIV-1 based lentiviral vectors in mouse liver" <i>Blood</i> <u>96</u> (3):1173-1176.

NY02:415587.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34690 (070050.1714)	Serial No. 09/621,781
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher, <i>et al.</i>	
	Filing Date July 21, 2000	Group 1636

	18 Soares C R <i>et al.</i> , 2000, "High-level synthesis of human prolactin in Chinese-Hamster ovary cells" <i>Biotechnol Appl Biochem.</i> <u>32</u> (Patient 2):127-135.
	19 Somia and Verma, 2000, "Gene therapy: trials and tribulations" <i>Nat Rev Genet.</i> <u>1</u> (2):91-99.
	20 Stiens L R <i>et al.</i> , 2000, "Development of serum-free bioreactor production of recombinant human thyroid stimulating hormone receptor" <i>Biotechnol Prog.</i> <u>16</u> (5):703-709.
	21 Su <i>et al.</i> , July 13 2000, "Cooperation between AP1 and PEA3 sites within the progression elevated gene-3 (PEG-3) promoter regulate basal and differential expression of PEG-3 during progression of the oncogenic phenotype in transformed rat embryo cells" <i>Oncogene</i> <u>19</u> (30):3411-3421.
	22 Su <i>et al.</i> , "Defining the regions within the promoter of progression elevated gene-3 responsible for differential expression during transformation progression", abstract submitted to be presented at the 91st Annual Meeting of the American Association for Cancer Research" in April 2000 but, according to e-mail correspondence from inventor Paul Fisher, never published.
	23 Symes J F, 2000, "Focal angiogenic therapy for myocardial ischemia" <i>J Card Surg.</i> <u>15</u> (4):283-290.
	25 Kumar A <i>et al.</i> , 1999, "Large-scale propagation of recombinant adherent cells that secrete a stable form of human glandular kallikrein, hK2" <i>Protein Expr Purif.</i> <u>15</u> (1):62-68.
	26 Lode H N <i>et al.</i> , 1999, "Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12" <i>Proc Natl Acad Sci USA</i> <u>95</u> (15):8591-8596.
	27 Su ZZ <i>et al.</i> , 1999, "PEG-3, a nontransforming cancer progression gene, is a positive regulator of cancer aggressiveness and angiogenesis" <i>Proc. Natl. Acad. Sci.</i> <u>96</u> (26):15115-15120.
	28 Toda M <i>et al.</i> , 1999, "Herpes simplex virus as an <i>in situ</i> cancer vaccine for the induction of specific anti-tumor immunity" <i>Hum Gene Ther.</i> <u>10</u> (3):385-393.

NY02:415587.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34690 (070050.1714)	Serial No. 09/621,781
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher, <i>et al.</i>	
	Filing Date July 21, 2000	Group 1636

31	Karin M <i>et al.</i> , 1997, "Current Opinion in Cell Biology" <i>AP-1 function and regulation</i> 9:240-246.
32	Olive M <i>et al.</i> , 1997, "A Dominant Negative to Activation Protein-1 (AP1) That Abolishes DNA Binding and Inhibits Oncogenesis" <i>The Journal of Biological Chemistry</i> 272(30):18586-18594.
33	D'Orazio D <i>et al.</i> , 1997, "Cooperation of two PEA3/AP1 sites in uPA gene induction by TPA and FGF-2" <i>Gene</i> 201:179-187.
34	De Cesare D <i>et al.</i> , 1996, "Functional characterization of COM, a DNA region required for cooperation between AP-1 sites in urokinase gene transcription" <i>Oncogene</i> 13:2551-2562.
35	Schweighoffer T <i>et al.</i> , 1996, "Adenovirus-enhanced receptor-mediated transferrin infection for the generation of tumor vaccines" <i>Cytokines Mol Ther.</i> 2(3):185-191.
36	Kohn E <i>et al.</i> , 1995, "Molecular Insights into Cancer Invasion: Strategies for Prevention and Intervention" <i>Cancer Research</i> 55:1856-1862.
37	Higashino F <i>et al.</i> , 1995, "Ets-related protein E1A-F can activate three different matrix metalloproteinase gene promoters" <i>Oncogene</i> 10:1461-1463.
38	Stacey K <i>et al.</i> , 1995, "Regulation of Urokinase-Type Plasminogen Activator Gene Transcription by Macrophage Colony-Stimulating Factor" <i>Molecular And Cellular Biology</i> 15(6):3430-3441.
39	Hartwell L <i>et al.</i> , 1994, "Cell Cycle Control and Cancer" <i>Science</i> 266(16):1821-1828.
40	Matrisian L M <i>et al.</i> , 1994, "Matrix Metalloproteinase Gene Expression" <i>Annals New York Academy of Sciences</i> 732:42-50.
41	Vogelstein B <i>et al.</i> , 1993, "The multistep nature of cancer" <i>TIG</i> 9(4):138-141.



NY02:415587.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34690 (070050.1714)	Serial No. 09/621,781
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher, <i>et al.</i>	
	Filing Date July 21, 2000	Group 1636



	42	Knudson A <i>et al.</i> , 1993, "Antioncogenes and human cancer" <i>Proc. Natl. Acad. Sci. USA</i> <u>90</u> :10914-10921.
	43	Levine A <i>et al.</i> , 1993, "The Tumor Suppressor Genes" <i>Annu. Rev. Biochem.</i> <u>62</u> :623-51.
	44	Reddy P <i>et al.</i> , 1993, "Identification and Cloning of Genes Involved in Progression of Transformed Phenotype" <i>Methods in Molecular Genetics</i> <u>1</u> :68-102.
	45	Wasylyk B <i>et al.</i> , 1993, "The Ets family of transcription factors" <i>Eur. J. Biochem.</i> <u>211</u> :7-18.
	46	Edwards D <i>et al.</i> , 1992, "Involvement of AP1 and PEA3 binding sites in the regulation of murine tissue inhibitor of metalloproteinases-1 (TIMP-1) transcription" <i>Biochimica et Biophysica Acta.</i> <u>1171</u> :41-55.
	47	Brown T <i>et al.</i> , 1992, "Specificities of protein-protein and protein-DNA interaction of GAP γ and two newly defined ets-related proteins" <i>Genes & Development</i> <u>6</u> :2502-2512.
	48	Macleod K <i>et al.</i> , 1992, "The ets gene family" <i>TIBS</i> <u>17</u> (7):251-256.
	49	Nerlov C <i>et al.</i> , 1992, "A regulatory element that mediates co-operation between a PEA3-AP-1 element and an AP-1 site is required for phorbol ester induction of urokinase enhancer activity in HepG2 hepatoma cells" <i>The EMBO Journal</i> <u>11</u> (12):4573-4582.
	50	Angel P <i>et al.</i> , 1991, "The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation" <i>Biochimica et Biophysica Acta</i> <u>1072</u> :129-157.
	51	Bishop M J <i>et al.</i> , 1991, "Molecular Themes In Oncogenesis" <i>Cell</i> <u>64</u> :235-248.
	52	Sirum-Connolly K <i>et al.</i> , 1991, "Interleukin-1 or phorbol induction of the stromelysin promoters requires an element that cooperates with AP-1" <i>Nucleic Acids Research</i> <u>19</u> (2):335-341.


NY02:415587.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34690 (070050.1714)	Serial No. 09/621,781
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant Fisher, <i>et al.</i>	
(Use several sheets if necessary)	Filing Date July 21, 2000	Group 1636




53	Duigou G J <i>et al.</i> , 1991, "Analysis of viral and cellular gene expression during progression and suppression of the transformed phenotype in type 5 adenovirus-transformed rat embryo cells" <i>Oncogene</i> <u>6</u> :1813-1824.
54	Liotta L A <i>et al.</i> , 1991, "Cancer Metastasis and Angiogenesis: An Imbalance of Positive and Negative Regulation" <i>Cell</i> <u>64</u> :327-336.
55	Duigou G J <i>et al.</i> , 1990, "Suppression of the Progression Phenotype in Somatic Cell Hybrids Occurs in the Absence of Altered Adenovirus Type 5 Gene Expression" <i>Molecular And Cellular Biology</i> <u>10</u> (5):2027-2034.
56	Gutman A <i>et al.</i> , 1990, "The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites" <i>The EMBO Journal</i> <u>9</u> (7):2241-2246.
57	Matrisian L M <i>et al.</i> , 1990, "Stromelysin/transin and tumor progression" <i>Seminars in Cancer Biology</i> <u>1</u> :107-115.
58	Duigou G J <i>et al.</i> , 1989, "Suppression of the Progression Phenotype by 5-Azacytidine in Rat Embryo Cells Doubly Transformed by Type 5 Adenovirus and the Ha-ras Oncogene" <i>Annals New York Academy of Science</i> <u>567</u> :302-306.
59	Wasylyk C <i>et al.</i> , 1989, "PEA3 is a nuclear target for transcription activation by non-nuclear oncogenes" <i>The EMBO Journal</i> <u>8</u> (11):3371-3378.
60	Babiss L E <i>et al.</i> , 1985, "Reversibility of Progression of the Transformed Phenotype in Ad5-Transformed Rat Embryo Cells" <i>Science</i> <u>228</u> :1099-1101.
61	Fisher P B <i>et al.</i> , 1984, "Mechanisms of Tumor Promotion" <i>Slaga T.J. (ed) CRC Press, Inc., Boca Raton, FL</i> , <u>3</u> :57-123.
62	Dignam J D <i>et al.</i> , 1983, "Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei" <i>Nucleic Acids Research</i> <u>11</u> (5):1475-1489.

NY02:415587.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) 	Atty. Docket No. A34690 (070050.1714)	Serial No. 09/621,781
	Applicant Fisher, <i>et al.</i>	
	Filing Date July 21, 2000	Group 1636

	63	Fisher P B <i>et al.</i> , 1982, "Analysis of type 5 adenovirus transformation with a cloned rat embryo cell line (CREF)" <i>Proc. Natl. Acad. Sci. USA</i> <u>79</u> :3527-3531.
	64	Fisher P B <i>et al.</i> , 1979, "Tumor Promoters and Epidermal Growth Factor Stimulate Anchorage-Independent Growth of Adenovirus-Transformed Rat Embryo Cells" <i>Cell</i> <u>18</u> :695-705.
	65	Fisher P B <i>et al.</i> , 1979, "Tumor Promoters Enhance Anchorage-Dependent Growth of Adenovirus-Transformed Cells without Altering the Integration Pattern of Viral Sequences" <i>Nature</i> <u>281</u> :591-594
	66	Fisher P B <i>et al.</i> , 1979, "Phenotypic Properties and Tumor Promoter-Induced Alterations in Rat Embryo Cells Transformed by Adenovirus" <i>Cancer Research</i> <u>39</u> :3051-3057.
	67	Fisher P B <i>et al.</i> , 1978, "Interactions between adenovirus, a tumor promoter, and chemical carcinogens in transformation of rat embryo cell cultures" <i>Proc. Natl. Acad. Sci USA</i> <u>75</u> (5):2311-2314.

NY02:415587.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.